ACHE and Cognitive impairment: Administration of ruthenium red (a RyRs antagonist) and montelukast (a CysLT1Rs antagonist) considerably attenuates CCH-induced cholinergic dysfunction by suppressing AChE activity, reducing the cognitive impairment and brain damage [80].